Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MRNS has been the subject of several other reports. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, Royal Bank of Canada lowered their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $0.31 on Monday. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26. The company has a market cap of $17.05 million, a price-to-earnings ratio of -0.13 and a beta of 1.26. The firm’s 50-day simple moving average is $1.17 and its 200 day simple moving average is $1.30.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. increased its stake in shares of Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after buying an additional 1,253,901 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Marinus Pharmaceuticals by 409.4% in the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 817,050 shares in the last quarter. abrdn plc grew its stake in shares of Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Marinus Pharmaceuticals by 70.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after purchasing an additional 183,396 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.